CASI Pharmaceuticals, Inc. CASI Cash Flow

Casi pharmaceuticals, inc. (CASI)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
-45,435	-45,362	-42,344	-41,430	-32,040	-27,471	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-10,770	-8,396	-8,476	-9,359	-9,453	-8,482	-8,393	-7,197	-7,206	-7,100	-27,033	-26,554	-26,202	-25,914	-5,817	-6,053	-5,738	-4,790	-4,535	-13,147	-14,545	-13,180	-13,300	-4,495	-4,558	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization for property and equipment
610	603	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization for property and equipment
-	-	-	-	-	-	-	-	165	117	87	71	65	66	65	67	70	68	66	62	58	48	37	27	19	17	18	20	20	20	19	23	30	38	0	0	0
Net loss on disposal of property and equipment
-1	-2	-1	-6	-6	-5	0	0	0	-	-	-	-	12	12	13	53	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	8	0	0	0
Amortization of intangible assets
1,540	1,550	1,542	1,482	1,441	1,305	945	597	250	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in the carrying amount of the right-of-use assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Gain) loss on disposal of intangible assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on disposal of intangible assets
-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation expense
7,332	7,310	7,921	7,616	7,741	6,119	3,652	2,112	754	650	1,310	1,369	2,779	2,995	2,549	2,645	1,513	1,541	1,530	2,196	2,216	2,189	2,342	1,744	2,197	2,044	1,786	1,674	932	978	789	544	381	609	0	0	0
Acquired in-process research and development
8,048	6,967	5,849	5,849	0	553	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of investment in equity securities
348	288	608	504	364	320	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on equity investment
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest
-	-	-	-	-	1	2	4	5	7	10	16	21	26	28	43	59	74	90	71	48	25	0	0	0	-	-	-	-	10,041	10,041	10,041	875	0	0	0	0
Change in fair value of contingent rights
-	-	-	-	-	-	-	-	-	19	15	-4	11	6	-5	-38	-32	-27	-35	6	-4	-11	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-23	0	23	23	23	0	0	0	-669	0	0	0	-1,263	0	0	0	-817	0	0	0
Inventories
1,878	4,411	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-5,264	-5,751	3,402	8,718	6,073	6,944	491	289	359	0	74	58	50	-86	-7	-90	-99	122	80	192	150	56	28	-92	150	90	77	94	15	9	27	-18	-36	-72	0	0	0
Accounts payable
2,865	4,001	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	-	271	849	285	237	336	180	117	-23	-211	129	201	395	403	352	247	-25	-57	-102	-132	22	-94	51	-7	-403	-654	-897	0	0	0
Payable to related party
-	-	-	-	-	-2,228	2,880	0	0	2,228	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-86	-55	0	0	86	0	0	0	-	-	-	-
Accrued liabilities and other liabilities
-613	-173	79	864	477	770	589	301	258	495	140	149	41	81	-7	-20	-17	5	5	11	11	1	14	19	18	11	-36	-217	-160	-99	-82	67	-7	-344	0	0	0
Net cash used in operating activities
-22,660	-23,243	-33,571	-32,915	-27,834	-28,584	-14,793	-12,272	-10,838	-6,402	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,391	-2,961	-3,788	-4,272	0	0	0
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from disposal of intangible assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,618	-5,744	-5,513	-5,322	-4,824	-4,315	-3,995	-3,608	-3,960	-4,025	-3,275	0	0	0	-	-	-	-	-	-	-	-
Proceeds from disposal of property and equipment
-	-	-	-	-	1	0	0	0	-	-	-	-	158	158	158	93	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56	0	0	0
Purchases of property and equipment
176	427	659	735	1,227	1,131	1,390	1,404	1,056	934	469	352	193	223	160	136	88	25	70	67	190	231	211	207	71	42	53	65	61	48	11	1	1	6	0	0	0
Acquisition of Abbreviated New Drug Applications and related items
-	-	-	-	-	20,643	18,608	18,607	18,607	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22	5	-25	-70	-301	-425	-466	-445	-207	-71	-42	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by (used in) investing activities
-27,357	-28,058	-22,581	-22,657	-3,262	-21,773	-19,997	-20,012	-19,664	-934	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11	-1	26	77	0	0	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible notes and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,000	10,000	10,000	10,000	0	0	0	0
Debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	683	683	683	683	0	0	0	0
Proceeds from sale of common stock and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,789	10,847	10,823	10,823	0	1	1,101	1,155	1,312	0	0	0
Repayment of loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	757	0	0	0
Stock issuance costs
225	190	74	184	617	822	1,218	1,108	674	462	24	30	38	96	72	66	57	0	0	0	0	-	-	-	-	448	448	464	539	88	0	0	0	-	-	-	-
Proceeds from sale of common stock
1,581	182	1,000	37,499	58,199	87,990	110,860	74,361	53,661	23,870	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash contribution from redeemable noncontrolling interest
0	20,000	20,000	20,000	20,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
4,648	854	114	119	197	258	583	502	424	325	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of stock options to satisfy tax withholding obligations
606	367	12	74	129	117	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants
2,580	3,275	4,541	3,695	4,682	4,961	2,088	1,960	973	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,176	10,223	0	0	0	0	-	-	-	-	10,401	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
6,269	22,045	22,700	61,055	82,333	92,270	113,196	75,661	54,384	23,733	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,229	9,221	10,306	389	0	0	0
Effect of exchange rate change on cash and cash equivalents
-2,101	-1,328	-2,174	-1,447	-1,391	-1,198	-1,179	-522	477	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-45,849	-30,584	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	24,358	16,397	-2,497	4,826	11,584	21,961	17,713	10,580	4,485	-5,538	-5,393	-5,125	-4,740	-4,461	-4,054	-4,143	-4,071	7,082	7,059	7,163	6,925	6,968	6,825	6,258	6,544	-3,805	0	0	0
Supplemental disclosure of cash flow information:
Interest paid
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest paid
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7	0	0	0
Income taxes paid
0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash financing activity:
Accrual for acquisition of in-process research and development
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant issued to placement agent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	115	115	115	115	0	0	0	0	-	-	-	-
Partial settlement of contingent rights derivative
-	-	-	-	-	-	-	-	-	-	-	-	-	5,279	3,232	3,044	1,922	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-